Delivery Order SPE2DB22D3501-SPE2DB25FXC80
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,455.09 to AmerisourceBergen Drug Corp for the supply of Verapamil 5 mg/2 mL vials on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price delivery order was not set-aside and represents a competitively awarded procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary distribution operations....
- The Defense Logistics Agency has awarded a delivery order valued at $2,723.92 to AmerisourceBergen Drug Corp for the supply of Verapamil 5 mg/2 ml vials. This firm fixed price delivery order, issued on July 18, 2025, represents a non-competitive, non-set-aside award to the pharmaceutical distributor's Conshohocken, Pennsylvania location, with an ultimate completion date of July 21, 2025. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Verapamil 5 mg/2 ml vials. The award has a completion date of March 1, 2024 and a potential value of $3,724.25. Amerisourcebergen Drug Corp is the prime contractor and there are no subcontractors mentioned. This delivery order is part of a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Verapamil SR 180 mg capsules (100-count units) with a ceiling value of $2,049.48. This contract represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for ultimate completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,379.19 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Verapamil ER PM 300 mg capsules (100-count units). This firm fixed-price delivery order, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive award. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,596.20, is for the delivery of verapamil 5 mg/2 ml vials. The contract has a completion date of February 19, 2025 and is a firm fixed-price delivery order. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Verapamil SR 180 mg capsules (100 count) with a ceiling value of $1,691.01 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of August 11, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,103.52 firm fixed-price contract is for the delivery of 4566683000 - VERAPAMIL 5 MG/2 ML VIAL 2ML, a cardiovascular medication, with a completion date of December 12, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Verapamil 5 mg/2 ml vials. The contract, valued at $1,772.86, is a firm fixed-price delivery order with a completion date of January 4, 2022. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of verapamil 5 mg/2 ml vials. The firm-fixed-price delivery order, valued at $4,384.79, has a completion date of July 17, 2024. This award is not associated with a set-aside program. Amerisourcebergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, including a $999,999,999 IDC with the DLA Troop...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXC80Delivery Order
The Defense Logistics Agency awarded a $9,032.46 delivery order to AmerisourceBergen Drug Corp for Verapamil 5 mg/2 mL vials on September 2, 2025, with completion expected by September 3, 2025. This non-set-aside contract utilizes firm fixed pricing and is performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order represents a small-value pharmaceutical procurement supporting federal medical supply requirements, consistent with the agency's routine acquisition of generic medications for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen leverages this comprehensive global contract vehicle to supply pharmaceutical products and medical commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. The company's substantial IDC portfolio and demonstrated capacity for competitive federal procurements position it as a primary supplier within DLA's pharmaceutical supply chain for military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 9/2/25 |